Skip to content
Colorectal Cancer Clinical Trials

Dallas, Texas

Colorectal cancer clinical trials in Dallas, TX

46 colorectal cancer studies are recruiting participants at sites in Dallas as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Dallas at a glance

  • 46 studies are recruiting at a site in Dallas.
  • By phase: Phase 1 (17), Phase 1/2 (13), Phase 2 (3), Phase 2/3 (2), Phase 3 (5), Phase 4 (2), Observational (4).
  • By sponsor: industry (41), university, hospital or other (5).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Dallas

Basic details from each study's public record (the 30 most recently updated of 46). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT05863195 · updated
  2. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Texas Oncology - DFW ( Site 8002) · UT Southwestern Medical Center ( Site 0059)
    Registry record
    NCT06997497 · updated
  3. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  4. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Parkland Memorial Hospital · UT Southwestern Simmons Cancer Center - RedBird · UT Southwestern/Simmons Cancer Center-Dallas
    Registry record
    NCT05174169 · updated
  5. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Jazz Pharmaceuticals
    Study site
    Texas Oncology - DFW
    Registry record
    NCT06695845 · updated
  6. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Texas Oncology - DFW (Sammons CC)
    Registry record
    NCT07213791 · updated
  7. Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Sairopa B.V.
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT05856981 · updated
  8. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Texas Oncology DFW · UT Southwestern
    Registry record
    NCT06662786 · updated
  9. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study sites
    Parkland Health and Hospital System · Texas Oncology DFW · UT Southwestern Medical Center
    Registry record
    NCT06750094 · updated
  10. A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kumquat Biosciences Inc.
    Study site
    START Dallas Fort Worth
    Registry record
    NCT07542704 · updated
  11. A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Texas Oncology
    Registry record
    NCT03526835 · updated
  12. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    UT Southwestern University Hospital Radiology Clinic
    Registry record
    NCT06710756 · updated
  13. [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

    • Phase 1/2
    • Ages 18 to 80
    • All sexes
    Sponsor
    Blue Earth Diagnostics
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT07432633 · updated
  14. A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Daiichi Sankyo
    Study site
    Texas Oncology, P.A.
    Registry record
    NCT06330064 · updated
  15. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study sites
    Mary Crowley Cancer Research · University of Texas Southwestern
    Registry record
    NCT04657068 · updated
  16. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kura Oncology, Inc.
    Study site
    UT Southwestern Simmons Cancer Center
    Registry record
    NCT06026410 · updated
  17. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    PMV Pharmaceuticals, Inc
    Study site
    UT Southwest Simmons Cancer Center
    Registry record
    NCT04585750 · updated
  18. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #89
    Registry record
    NCT05176483 · updated
  19. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study sites
    SCRI at Mary Crowley · University of Texas Southwestern Medical Center
    Registry record
    NCT06625775 · updated
  20. DESTINY-PANTUMOUR04

    • Observational
    • Ages 18 to 130
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07124000 · updated
  21. A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT07277270 · updated
  22. Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Neonc Technologies, Inc.
    Study site
    Baylor, Scott and White Research Institute
    Registry record
    NCT06047379 · updated
  23. Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    NEXT - Dallas
    Registry record
    NCT07349537 · updated
  24. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Study site
    UT Southwestern Medical Center
    Registry record
    NCT05059444 · updated
  25. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    Mary Crowley Cancer Research
    Registry record
    NCT06253871 · updated
  26. Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Stingray Therapeutics
    Study site
    Texas Oncology- Sammons- DFW
    Registry record
    NCT06589440 · updated
  27. A Study of ASP1002 in Adults for Treatment of Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Mary Crowley Cancer Research Center
    Registry record
    NCT05719558 · updated
  28. A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer

    • Phase 4
    • Ages 18 and older
    • All sexes
    Sponsor
    Takeda
    Study site
    University of Texas Southwestern Medical Center
    Registry record
    NCT06562543 · updated
  29. A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pilatus Biosciences Inc
    Study site
    NEXT Dallas
    Registry record
    NCT07337525 · updated
  30. Randomizing Two Radiotherapy Boost Options to Avoid Rectal Cancer Surgery

    • Phase 2/3
    • Ages 18 to 80
    • All sexes
    Sponsor
    Sir Mortimer B. Davis - Jewish General Hospital
    Study site
    UT Southwestern Medical Center
    Registry record
    NCT03051464 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Dallas, TX on ClinicalTrials.gov.

Ask about studies near Dallas

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call